Jubilant Life zooms 10% as firm gets USFDA nod for drug

Jubilant Life Sciences shares soared almost 10 per cent, to touch its 52-week high level today, as the company received final approval from the US health regulator for its generic version of anti-depressant Paxil tablets.
The stock zoomed 9.75 per cent to Rs 452.40, its 52-week high, on BSE.
At NSE, shares of the company soared 9.25 per cent to touch its one-year peak of Rs 452.50.
The final approval for the abbreviated new drug application (ANDA) from the US Food and Drug Administration (USFDA) for Paroxetine tablets of Apotex is for the strengths of 10 mg, 20 mg, 30 mg and 40 mg, the company said in a BSE filing today.

As on September 30, 2015, Jubilant Life Sciences had a total of 820 filings for formulations, of which 391 have been approved in various regions globally.
These include 71 ANDAs filed in the US, of which 39 have been approved and 46 Dossier filings in Europe, it said.